You are viewing the site in preview mode

Skip to main content

Table 1 Laboratory test indicators of the patient

From: Recurrent Wunderlich syndrome in systemic lupus erythematosus: a case report

Indicators

Baseline

First WS

First TAE

Second WS

Second TAE

Normal range

SLICC criteria

White blood cell (*10^9/L)

9.9

6.92

12.37

14.07

12.5

3.5–9.5

 

Red blood cell (*10^12/L)

2.41

1.38

1.64

1.1

2.62

3.80–5.10

 

Lymphocyte (*10^9/L)

0.66

0.31

0.68

0.28

0.12

1.1–3.2

 

Lymphocyte (%)

7.2

4.5

5.5

2

1

20.0–50.0

 

Hemoglobin (g/L)

75

42

50

35

81

115.0-150.0

 

Platelet (*10^9/L)

96

70

82

111

114

125.0-350.0

Clinical criteria

Neutrophils (*10^9/L)

7.8

6.39

10.91

13.17

12.16

1.8–6.3

 

Neutrophils (%)

85.3

92.3

88.2

93.6

97.2

40.0–75.0

 

Total protein (g/L)

47.6

38.4

 

44.8

48.3

66.0–87.0

 

Albumin (g/L)

32.8

24.7

 

30.4

31.7

40.0–55.0

 

Globulin (g/L)

14.8

13.7

 

14.4

16.6

20–35

 

ALT (U/L)

10

9

 

13

14

7–40

 

AST (U/L)

20

15

 

24

20

13–35

 

LDH (U/L)

300

200

 

380

371

120–250

 

Creatinine (µmol/L)

225

260

 

509

415

45–84

 

eGFR (ml/min/1.73m^2)

17.9

15.7

 

6.7

8.5

> 90

 

KDIGO classification

CKD G4

AKI Stage 1

 

AKI Stage 2

   

Urea (mmol/L)

14.1

14.3

 

24.2

24.7

3.1–8.8

 

Uric acid (µmol/L)

434

446

 

517

463

142.8-339.2

 

Cholesterol (mmol/L)

3.17

2.21

 

3.06

3.16

< 5.18

 

Total bilirubin (µmol/L)

8.2

6.6

 

8.6

10.7

≤ 23

 

APTT (s)

40.1

 

45.9

 

39.5

29.0–42.0

 

Thrombin time (s)

18.9

 

19.2

 

17.9

<21.0

 

Prothrombin activity (%)

106

 

90

 

117

80.0-135.0

 

Prothrombin time (s)

12.9

 

13.8

 

12.4

11.5–14.5

 

Fibrinogen (g/L)

2.4

 

1.81

 

2.17

2.00–4.00

 

D-D dimer (µg/mL FEU)

2.08

 

1.96

 

2.38

< 0.5

 

FDP (µg/mL)

    

10

< 5.0

 

Amylopsin (U/L)

55

    

15–53

 

Pancreatic lipase (IU/L)

67.7

    

13–60

 

NT-proBNP (pg/mL)

2417

2873

   

< 738

 

Troponin I (µg/L)

28.1

    

≤ 15.6

 

Complement 3 (g/L)

0.64

0.74

   

0.8–1.8

Immunology criteria

Complement 4 (g/L)

0.17

0.21

   

0.1–0.4

Immunology criteria

IgA (g/L)

0.59

0.34

   

0.7-4.0

 

IgG (g/L)

1.74

4.11

   

7.0–16.0

 

IgM (g/L)

0.25

0.17

   

0.4–2.3

 

C-reactive protein (mg/L)

6.19

24.1

   

0–10.0

 

IL-10 (pg/ml)

5.9

    

0.1-5.0

 

IL-2 (pg/ml)

1.39

    

0.1–4.1

 

IL-4 (pg/ml)

1.23

    

0.1–3.2

 

IL-6 (pg/ml)

5.3

    

0.1–2.9

 

IFN-r (pg/ml)

1.78

    

0.1–18.0

 

TNF-α (pg/ml)

1.1

    

0.1–23

 

ACA

negative

    

negative

 

LAC

negative

    

negative

 

GM/G test

negative

    

negative

 

Coomb's test

negative

    

negative

 

Urine protein

3+

    

negative

Clinical criteria

ANA

1:320 nucleolar type

    

negative

Immunology criteria

Anti-dsDNA

negative

    

negative

 

Anti-Sm

positive

    

negative

Immunology criteria

Anti-RO52

positive

    

negative

 

Anti-CCP (RU/ml)

< 2.00

    

0–20

 

AKA

negative

    

negative

 

ASO (IU/ml)

2.75

    

0-250

 

RF (IU/ml)

16

    

0–30

 

ANCA

negative

    

negative

 
  1. ALT: Alanine aminotransferase, KDIGO: Kidney Disease: Improving Global Outcomes, CKD: Chronic kidney disease, AKI: Acute kidney injury, AST: Aspartate aminotransferase, LDH: Lactic dehydrogenase, eGFR: estimated glomerularfiltrationrate, UA: Uric acid, CRP: C-reactive protein, APTT: Activated partial thromboplastin time, FDP: Fibrinogen degradation products, ACA: Anticardiolipin antibody, LAC: Lupus anticoagulant, RSV: Respiratory syncytial virus, CCP: Cyclic citrullinated peptide antibody, AKA: Anti-keratin antibody, ASO: Antistreptolysin, RF: Rheumatoid arthritis, ANA: Antinuclear antibodies, dsDNA: Double-stranded deoxyribonucleic acid, ANCA: Anti-neutrophil cytoplasmic antibodies, SLICC: Systemic Lupus International Collaborating Clinics